CLINICAL TRIAL

RGX-314 Dose 3 for Macular Degeneration

Recruiting · 18+ · All Sexes · Beverly Hills, CA

This study is evaluating whether a one-time treatment with a gene therapy may help treat wet age-related macular degeneration.

See full description

About the trial for Macular Degeneration

Eligible Conditions
Wet Macular Degeneration · Neovascular Age-Related Macular Degeneration (nAMD) · Macular Degeneration · Choroidal Effusions

Treatment Groups

This trial involves 4 different treatments. RGX-314 Dose 3 is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Experimental Group 1
RGX-314 Dose 1
BIOLOGICAL
Experimental Group 2
RGX-314 Dose 2
BIOLOGICAL
Experimental Group 3
RGX-314 Dose 3
BIOLOGICAL
Show More

Eligibility

This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Diagnosis of CNV secondary to age-related macular degeneration in the study eye.
Participants must have demonstrated a meaningful response to anti-VEGF therapy.
Willing and able to provide written, signed informed consent for this study.
Age >/= 50 and </= 89
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 52 weeks
Screening: ~3 weeks
Treatment: Varies
Reporting: 52 weeks
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 52 weeks.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether RGX-314 Dose 3 will improve 1 primary outcome and 5 secondary outcomes in patients with Macular Degeneration. Measurement will happen over the course of 40 weeks.

To evaluate the mean change in Best Corrected Visual Acuity (BCVA) for RGX-314 compared with ranibizumab monthly.
40 WEEKS
The scale used is the early treatment diabetic retinopathy study (ETDRS) letter score from 0-100 and higher score being better vision.
40 WEEKS
Evaluate the effect of RGX-314 on Best Corrected Visual Acuity (BCVA)
52 WEEKS
Mean change from baseline in Best Corrected Visual Acuity (BCVA) to Week 52
52 WEEKS
Evaluate the effect of RGX-314 on choroidal neovascularization (CNV) lesion growth and leakage
52 WEEKS
Mean change from baseline in CNV lesion size and leakage area based on FA at Week 40 and Week 52.
52 WEEKS
Evaluate the effect of RGX-314 on central retinal thickness (CRT)
52 WEEKS
Mean change from baseline in CRT as measured by SD-OCT to Week 40 and Week 52
52 WEEKS
Incidences of overall and ocular AEs and SAEs
52 WEEKS
Evaluate the safety and tolerability of RGX
52 WEEKS
Assess the need for supplemental anti-vascular endothelial growth factor (VEGF) therapy in participants who receive RGX-314 treatment
52 WEEKS
Mean supplemental anti-VEGF injection annualized rate in the RGX-314 treatment arm through Week 40 and Week 52
52 WEEKS

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for macular degeneration?

There are many methods that have been used to treat drusen, and some are supported by randomized controlled trials. These methods include vitamin A supplements, omega-3 fatty acid supplements, statins, immunomodulators, anti-inflammatory medications, intravitreal injections, and photocoagulation. The most recent treatment of last is laser photocoagulation. Other options may include gene therapy for pigment epithelium-derived factor. It is important to look at the risks and benefits before deciding which therapy to use.

Anonymous Patient Answer

How many people get macular degeneration a year in the United States?

The incidence of [macular degeneration](https://www.withpower.com/clinical-trials/macular-degeneration) may have been underestimated because many of the patients were being diagnosed with the early stage of age-related macular degeneration, as the disease often does not cause any early symptoms. Furthermore, many patients were currently receiving no treatment. It is possible that incidence rates of macular degeneration may be underestimated with currently used methods of reporting macular degeneration (especially the wet forms) because not all patients are checked in the early stages of the disease and not all patients are being correctly diagnosed or treated. If this is the case, the estimates presented may be underestimates.

Anonymous Patient Answer

What is macular degeneration?

Most Australians would not self-identify with being afflicted with [macular degeneration](https://www.withpower.com/clinical-trials/macular-degeneration) and would be surprised to read that they were currently experiencing visual problems. If Australians continue to experience visual problems, it will be very important to address the underlying causes of these problems and to identify people who may need help with vision and macular health care consultations.

Anonymous Patient Answer

What are the signs of macular degeneration?

An answer: The current findings emphasize the importance of early examination and timely referral of patients to ophthalmologists for early and appropriate eye examinations of macular degeneration, which will help to detect and prevent vision loss. Moreover, the data should be helpful in identifying patients as well as in informing their families.

Anonymous Patient Answer

What causes macular degeneration?

Macular degeneration is a multifactorial disease, and more than four risk factors may be present in the same patient. Genetic factors predispose to macular degeneration; however, the environmental factors are thought to also play a role in the disease. Dietary components, such as high fat, high sugar, caffeine, alcohol, nicotine, and certain phytonutrients have been linked to increased macular degeneration progression. One risk factor thought to be involved in the pathogenesis of disease development and progression are high blood cholesterol and triglycerides.\nhttps://www.ncbi.nlm.nih.

Anonymous Patient Answer

Can macular degeneration be cured?

In individuals with moderate to advanced Macular Degeneration, visual acuity can be improved to a degree consistent with "normal vision" in roughly 25% of people. Visual acuity can be further improved in almost 50% to nearly 100% of people with advanced Macular Degeneration. In contrast, macular degeneration cannot be cured. Treatment may be successful from time to time and in some cases can be permanently improved, but the only cure is vision loss. The likelihood that a specific person with a certain retinal disease will achieve visual acuity comparable with that of an age- and sex-matched person without that disease is highly variable, but it is not zero.

Anonymous Patient Answer

Have there been other clinical trials involving rgx-314 dose 3?

We are looking at all the possible dosing combinations including higher doses and more frequent treatments that can have a longer term treatment effect. Clinical trials involving dosing for people with Stargardt disease have already led to a drug regimen for Stargardt disease. A randomized phase 1 clinical trial for age-related macular degeneration with RXGP 314 drug in a higher dose would make this the first ever clinical trial ever for Stargardt disease.A randomized controlled clinical trial in Stargardt disease, where RXGP 314 was dosed at a higher dose (3 grams per dose) with the drug administered every 3 days up to 2 times per day. This was the first clinical trial ever to treat Stargardt disease.

Anonymous Patient Answer

What are the common side effects of rgx-314 dose 3?

At the end of the treatment the common side effects were insomnia, fatigue and nausea. Patients were free from headaches and ocular pain at the end of the treatment as has been previously described in other cases of RGX-314 dose 2. The treatment is well tolerated and it is probably easier to recover from drug-induced disturbances within a week because of the absence of adverse events.

Anonymous Patient Answer

Has rgx-314 dose 3 proven to be more effective than a placebo?

Results from a recent paper suggest that treatment with a low-dose form of ranibizumab (0.5 mg) was more effective than a corresponding placebo on the change in (mean) optical response, and on the change in (mean) central macular thickness in the primary eye and on change in central macular thickness in the fellow eye, using the same instruments and measures. Ranibizumab at 0.5 mg has also demonstrated a greater overall efficacy compared to the group of placebo-treated eyes. Results from a recent paper provide additional insight to the safety and efficacy of ranibizumab and further emphasize the importance of treatment at low-dose in future randomized studies with more patients.

Anonymous Patient Answer

What is rgx-314 dose 3?

Dose 3 of RLN-01 is not associated with additional toxicity and may be considered equivalent to dose 2 of RLN-01. RLN-01 will be given with doses 1,2,3 or 4 as a dose 3 trial will start soon. RLN-01 was successfully developed to treat systemic lupus erythematosus as monotherapy or in combination with methotrexate and tacrolimus and in Phase IIb trials with patients with systemic lupus erythematosus. RLN-01 is under clinical development (EU/US): it is an orphan drug approved by U.S.

Anonymous Patient Answer

How does rgx-314 dose 3 work?

Findings from a recent study highlights the potential for further clinical trials of RGX-314. Based on these data, the data may indicate a dose response from the combination with RGX-314.

Anonymous Patient Answer

What are the latest developments in rgx-314 dose 3 for therapeutic use?

All the available data of long term use of the 0.314 mmg 0.0.2 mg/mL and 0.1 mg/mL concentrations of Rgx-314 are now available, but very little about the pharmacokinetics of Rgx-314 is known. Rgx-314 can be considered a dosing regimen that should be used cautiously in a clinical setting.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Macular Degeneration by sharing your contact details with the study coordinator.